SCHEMBL2763191

SCHEMBL2763191

O=S(=O)(Nc1nc(-c2ccccc2Cl)cs1)c1sc(Cl)cc1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 10/20 0.61
GSTO1 P78417 1/20 0.48
MAOA P21397 4/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 1/20 0.46
RORC P51449 1/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP1A1 P04798 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP1B1 Q16678 1/20 0.44
HSD11B1 P28845 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832138 0.81 CA1 (0.49) KDM1AKMT2AMEN1POLBLMNA
SCHEMBL5830803 0.80 CCR4 (0.42) KDM1AMAOAKMT2AMEN1LMNA
SCHEMBL2762650 0.79 KDM1A (0.66) KDM1AGSTO1MAOAKMT2AMEN1
SCHEMBL2762590 0.79 KDM1A (0.72) KDM1AGSTO1MAOAKMT2AMEN1
SCHEMBL6612903 0.78 CCKBR (0.43) KDM1APOLBSMN1; SMN2KDM4E
SCHEMBL6612818 0.75 CCKBR (0.43) KDM1AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL2762642 0.74 KDM1A (0.74) KDM1AMAOAKMT2AMEN1POLB
SCHEMBL2762814 0.74 KDM1A (0.63) KDM1AGSTO1MAOAKMT2AMEN1
SCHEMBL2762551 0.74 KDM1A (0.65) KDM1AGSTO1MAOAKMT2AMEN1
SCHEMBL2762518 0.74 KDM1A (0.65) KDM1AGSTO1MAOAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KDM1A 1332/4885GSTO1 208/4885MAOA 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.